Enanta Pharmaceuticals ENTA
NASDAQ ENTA
$12.61 -0.23 (-1.82%)
As of: Oct 2, 2026 · 2:45 PM EDT

Enanta Pharmaceuticals (ENTA) Return on Assets [ROA] (2013 - 2026)

Updated

Enanta Pharmaceuticals (ENTA) posted Return on Assets [ROA] of -20.68% for fiscal Q3 2026 (quarter ended Jun 30, 2026), up 8.81 percentage points from -29.49% a year earlier but down 1.43 percentage points from the prior quarter.

Analysis

Enanta Pharmaceuticals (ENTA) Return on Assets [ROA] (2013 - 2026) Analysis & Trends

For FY2025 (ended Sep 30, 2025), Enanta Pharmaceuticals' Return on Assets [ROA] came in at -24.91%, up 2.75 percentage points from FY2024.

  • Annual Return on Assets [ROA] shows a five-year change of -17.50 percentage points (FY2020 to FY2025).
  • In prior fiscal years, Enanta Pharmaceuticals' Return on Assets [ROA] was -27.67% in FY2024 (+4.28 pp), -31.95% in FY2023 (-2.04 pp), -29.91% in FY2022 (-12.83 pp) and -17.08% in FY2021 (-9.67 pp).
  • Quarterly Return on Assets [ROA] has run from a low of -37.00% in fiscal Q2 2023 to a high of -19.24% in fiscal Q2 2026 over five years.
  • On a year-over-year basis, Return on Assets [ROA] has increased in each of the last four quarters, with an average year-over-year change of +3.39 percentage points over the last eight quarters.
  • The strongest year-over-year quarter for Return on Assets [ROA] in the past five years was fiscal Q2 2026, with a gain of 9.47 percentage points; the weakest was fiscal Q1 2022, with a drop of 14.17 percentage points.
  • According to Business Quant data, Return on Assets [ROA] for the three prior fiscal quarters was -19.24% (Q2 2026), -23.45% (Q1 2026) and -28.15% (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROA (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 10.47%
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 4.65%
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 2.45%
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 28.37%
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 9.10%
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 9.29%
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -6.13%
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 2.14%
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 16.34%
10 Enanta Pharmaceuticals 383.80 Mn -344.19 Mn - -20.68%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -20.68%
Mar 31, 2026 -19.24%
Dec 31, 2025 -23.45%
Sep 30, 2025 -28.15%
Jun 30, 2025 -29.49%
Mar 31, 2025 -28.71%
Dec 31, 2024 -28.93%
Sep 30, 2024 -29.93%
Jun 30, 2024 -28.39%
Mar 31, 2024 -31.29%
Dec 31, 2023 -31.04%
Sep 30, 2023 -27.95%
Jun 30, 2023 -32.15%
Mar 31, 2023 -37.00%
Dec 31, 2022 -33.37%
Sep 30, 2022 -32.01%
Jun 30, 2022 -30.30%
Mar 31, 2022 -26.51%
Dec 31, 2021 -26.16%
Sep 30, 2021 -20.97%
API Access

Enanta Pharmaceuticals Return on Assets [ROA] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-assets-%5Broa%5D&ticker=ENTA&period=max&api_key=YOUR_API_KEY